Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

Eytan M. Stein, Andriy Derkach, Gabrielle Melamed, Alana Block, Janet Kim, Gergana Georgieva, Vanessa Thompson, Ross L Levine, Andrew M. Intlekofer, Omar Abdel-Wahab, Martin S. Tallman

Blood (2023) 142 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2023-190801

Published: 2023

Journal Articles

Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Amer M. Zeidan, Santosh Gautam, Rebekah Yu, Ziyu Lan, David L. Grinblatt, Dina ElSouda, James Spalding, Alana Block, Maelys Touya, Bhavik J. Pandya

Blood (2022) 140 (Supplement 1): 8124–8126.

https://doi.org/10.1182/blood-2022-166692

Published: 2022

Journal Articles

Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study

Lori Muffly, Christopher Young, Bin Xie, Alana Block, Maelys Touya, Bhavik J. Pandya

Blood (2022) 140 (Supplement 1): 8111–8112.

https://doi.org/10.1182/blood-2022-157964

Published: 2022